SG11201700978SA - Method for enhancing immune cell function and method for assessing immune cell multifunctionality - Google Patents
Method for enhancing immune cell function and method for assessing immune cell multifunctionalityInfo
- Publication number
- SG11201700978SA SG11201700978SA SG11201700978SA SG11201700978SA SG11201700978SA SG 11201700978S A SG11201700978S A SG 11201700978SA SG 11201700978S A SG11201700978S A SG 11201700978SA SG 11201700978S A SG11201700978S A SG 11201700978SA SG 11201700978S A SG11201700978S A SG 11201700978SA
- Authority
- SG
- Singapore
- Prior art keywords
- immune cell
- multifunctionality
- assessing
- enhancing
- cell function
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title 2
- 230000003915 cell function Effects 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/55—IL-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014166593 | 2014-08-19 | ||
JP2015085556 | 2015-04-20 | ||
PCT/JP2015/073011 WO2016027764A1 (en) | 2014-08-19 | 2015-08-17 | Method for enhancing immune cell function and method for assessing immune cell multifunctionality |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201700978SA true SG11201700978SA (en) | 2017-03-30 |
Family
ID=55350709
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202005315SA SG10202005315SA (en) | 2014-08-19 | 2015-08-17 | Agent for treating and/or preventing diseases associated with immune abnormalities by combining biguanide antidiabetic drug with immunosuppressive factor blocking agent or costimulatory receptor agonist |
SG11201700978SA SG11201700978SA (en) | 2014-08-19 | 2015-08-17 | Method for enhancing immune cell function and method for assessing immune cell multifunctionality |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202005315SA SG10202005315SA (en) | 2014-08-19 | 2015-08-17 | Agent for treating and/or preventing diseases associated with immune abnormalities by combining biguanide antidiabetic drug with immunosuppressive factor blocking agent or costimulatory receptor agonist |
Country Status (15)
Country | Link |
---|---|
US (2) | US20170231929A1 (en) |
EP (2) | EP3232199B1 (en) |
JP (3) | JP6629211B2 (en) |
KR (1) | KR20170042778A (en) |
CN (1) | CN107148274A (en) |
AU (1) | AU2015304448B2 (en) |
BR (1) | BR112017002807A2 (en) |
CA (1) | CA2958573A1 (en) |
ES (1) | ES2915849T3 (en) |
IL (1) | IL250639B (en) |
MX (1) | MX2017002134A (en) |
PH (1) | PH12017500224A1 (en) |
RU (2) | RU2731098C2 (en) |
SG (2) | SG10202005315SA (en) |
WO (1) | WO2016027764A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1896582A4 (en) * | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
ME03527B (en) | 2013-12-12 | 2020-04-20 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
CN117586403A (en) | 2016-10-11 | 2024-02-23 | 艾吉纳斯公司 | anti-LAG-3 antibodies and methods of use thereof |
CN107082812B (en) | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | It is a kind of restore debilitating immune cell function fusion protein and its application |
CN110662540B (en) * | 2017-06-02 | 2024-01-26 | 拜耳医药保健有限责任公司 | Combination of regorafenib and a PD-1/PD-L1 (2) inhibitor for the treatment of cancer |
JPWO2019069449A1 (en) * | 2017-10-06 | 2019-11-14 | 純児 赤木 | Measuring method |
JPWO2019124423A1 (en) * | 2017-12-19 | 2020-10-22 | 国立大学法人 岡山大学 | Cancer progression control, treatment, prevention and / or recurrence prevention agent |
JP2019112353A (en) * | 2017-12-25 | 2019-07-11 | 合同会社チューモス | Autologous tumor vaccine and immune induction method |
US11959916B2 (en) * | 2017-12-26 | 2024-04-16 | Tamio Yamauchi | Method, system, and program for supplying immunodynamics-related information |
IL264068B2 (en) * | 2018-01-05 | 2023-07-01 | Great Novel Therapeutics Biotech & Medicals Corp | A combination and pharmaceutical composition comprising an hdac inhibitor, an nsaid in combination with an immune check point inhibitor for use in a method of removing immune suprresion in a tumor microenviroment or stimulating an immune system sgainst cancer cells |
WO2019202473A1 (en) * | 2018-04-16 | 2019-10-24 | Université de Lausanne | Ucp2 inducing agents for the treatment of cancer resistant to immune checkpoint blockade |
WO2020118208A1 (en) * | 2018-12-07 | 2020-06-11 | Arizona Board Of Regents On Behalf Of The University Of Arizona | A method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring pd-1/pd-l1 signaling pathway members |
KR102510381B1 (en) * | 2019-10-16 | 2023-03-15 | 한국과학기술원 | An Immunotherapeutic agent composition for preventing or treating brain cancer comprising metformin as an active reagent |
WO2022072745A1 (en) * | 2020-10-01 | 2022-04-07 | The Regents Of The University Of California | Methods and compositions to treat and prevent viral infections and acute respiratory distress syndrome |
CN112791182A (en) * | 2020-12-31 | 2021-05-14 | 中山大学 | Application of pharmaceutical composition of metformin and anti-PD-1 antibody in preparation of liver cancer drugs |
CN113421627B (en) * | 2021-05-11 | 2023-04-07 | 深圳市罗湖区人民医院 | System for evaluating anti-aging effect of drug on NK (natural killer) cells in vitro |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0624207B2 (en) * | 1986-06-25 | 1994-03-30 | 新電元工業株式会社 | High-voltage semiconductor device manufacturing method |
US4938949A (en) * | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
US5260275A (en) * | 1990-08-14 | 1993-11-09 | Amylin Pharmaceuticals, Inc. | Hypoglycemics |
CA2174132A1 (en) * | 1993-10-14 | 1995-04-20 | Immunex Corporation | Fas antagonists and uses thereof |
CA2416767A1 (en) * | 2000-08-07 | 2002-02-14 | Ranbaxy Signature Llc | Liquid formulation of metformin |
ATE481985T1 (en) * | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | IMMUNOPOTENTATING COMPOSITIONS |
EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
US8563500B2 (en) * | 2007-09-05 | 2013-10-22 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Methods and compounds for treating diseases caused by reactive oxygen species |
JP2013503171A (en) * | 2009-08-25 | 2013-01-31 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Use of metformin in the treatment and prevention of cancer |
US20130059916A1 (en) * | 2010-05-26 | 2013-03-07 | Stephane Rocchi | Biguanide compounds and its use for treating cancer |
BR112013017499A2 (en) * | 2011-01-11 | 2016-09-27 | Univ Basel | combination of sirosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression |
WO2013009535A1 (en) * | 2011-07-08 | 2013-01-17 | Merck Sharp & Dohme Corp. | Il-23 antagonists for treatment or prevention of skin rash associated with treatment with p13k/akt pathway inhibitors |
CN103371991A (en) * | 2012-04-18 | 2013-10-30 | 中国人民解放军第二军医大学 | Application of dimethyldiguanide in preparation of medicaments for preventing or treating hepatocellular carcinoma |
PL2872646T3 (en) * | 2012-07-12 | 2018-03-30 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
SG11201500922RA (en) * | 2012-08-06 | 2015-04-29 | Inserm Inst Nat De La Santé Et De La Rech Médicale | Methods and kits for screening patients with a cancer |
SG10201702421TA (en) * | 2012-10-02 | 2017-05-30 | Bristol Myers Squibb Co | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
WO2014083095A1 (en) * | 2012-11-29 | 2014-06-05 | Universitaet Basel | Combinations of metformin with other compounds for the treatment of cancer and for immunosuppression |
DK2941258T3 (en) * | 2013-01-02 | 2019-12-16 | Decoy Biosystems Inc | COMPOSITIONS AND PROCEDURES FOR TREATING CANCER USING BACTERIA |
JP6242071B2 (en) * | 2013-04-23 | 2017-12-06 | 国立大学法人 岡山大学 | Immune exhausted CD8 + T cell function improving agent, cancer therapeutic agent and preventive or therapeutic agent for metabolic syndrome |
-
2015
- 2015-08-17 AU AU2015304448A patent/AU2015304448B2/en not_active Ceased
- 2015-08-17 CN CN201580043408.XA patent/CN107148274A/en active Pending
- 2015-08-17 RU RU2017108754A patent/RU2731098C2/en active
- 2015-08-17 BR BR112017002807A patent/BR112017002807A2/en not_active IP Right Cessation
- 2015-08-17 SG SG10202005315SA patent/SG10202005315SA/en unknown
- 2015-08-17 CA CA2958573A patent/CA2958573A1/en not_active Abandoned
- 2015-08-17 US US15/503,247 patent/US20170231929A1/en not_active Abandoned
- 2015-08-17 RU RU2020127099A patent/RU2020127099A/en unknown
- 2015-08-17 WO PCT/JP2015/073011 patent/WO2016027764A1/en active Application Filing
- 2015-08-17 EP EP17174222.4A patent/EP3232199B1/en active Active
- 2015-08-17 ES ES17174222T patent/ES2915849T3/en active Active
- 2015-08-17 JP JP2016544195A patent/JP6629211B2/en active Active
- 2015-08-17 SG SG11201700978SA patent/SG11201700978SA/en unknown
- 2015-08-17 MX MX2017002134A patent/MX2017002134A/en unknown
- 2015-08-17 KR KR1020177007514A patent/KR20170042778A/en not_active Application Discontinuation
- 2015-08-17 EP EP15833898.8A patent/EP3192517A4/en not_active Withdrawn
-
2017
- 2017-02-07 PH PH12017500224A patent/PH12017500224A1/en unknown
- 2017-02-16 IL IL250639A patent/IL250639B/en active IP Right Grant
- 2017-04-20 JP JP2017083767A patent/JP6672217B2/en active Active
- 2017-06-20 US US15/628,600 patent/US20170281569A1/en not_active Abandoned
-
2020
- 2020-03-03 JP JP2020035992A patent/JP2020109098A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170281569A1 (en) | 2017-10-05 |
EP3232199A8 (en) | 2017-12-13 |
AU2015304448A1 (en) | 2017-03-09 |
AU2015304448B2 (en) | 2020-04-30 |
IL250639B (en) | 2020-02-27 |
EP3232199A2 (en) | 2017-10-18 |
RU2731098C2 (en) | 2020-08-28 |
RU2020127099A (en) | 2020-09-02 |
EP3192517A1 (en) | 2017-07-19 |
CA2958573A1 (en) | 2016-02-25 |
PH12017500224B1 (en) | 2017-07-10 |
US20170231929A1 (en) | 2017-08-17 |
IL250639A0 (en) | 2017-04-30 |
BR112017002807A2 (en) | 2017-12-19 |
JPWO2016027764A1 (en) | 2017-06-01 |
SG10202005315SA (en) | 2020-07-29 |
PH12017500224A1 (en) | 2017-07-10 |
MX2017002134A (en) | 2017-09-13 |
WO2016027764A1 (en) | 2016-02-25 |
JP6629211B2 (en) | 2020-01-15 |
EP3232199B1 (en) | 2022-05-04 |
ES2915849T3 (en) | 2022-06-27 |
RU2017108754A3 (en) | 2019-03-29 |
JP6672217B2 (en) | 2020-03-25 |
RU2017108754A (en) | 2018-09-20 |
JP2017165752A (en) | 2017-09-21 |
EP3232199A3 (en) | 2018-02-14 |
EP3192517A4 (en) | 2018-04-25 |
CN107148274A (en) | 2017-09-08 |
KR20170042778A (en) | 2017-04-19 |
JP2020109098A (en) | 2020-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250639B (en) | Method for enhancing immune cell function and method for assessing immune cell multifunctionality | |
IL252126A0 (en) | Methods for transduction and cell processing | |
GB201617433D0 (en) | Evaluation system and method | |
HK1255101A1 (en) | Methods for obtaining regulatory t cells and uses thereof | |
HUE045019T2 (en) | Quick-charging method and system | |
PT3101760T (en) | Charging method and system | |
GB201408100D0 (en) | Detection method | |
HK1243177A1 (en) | Parallel cell processing method and facility | |
GB201421135D0 (en) | Assessment method | |
GB2523776B (en) | Methods for 3D object recognition and pose determination | |
GB201419330D0 (en) | Detection method | |
HK1220676A1 (en) | Arrangement and method | |
HK1221307A1 (en) | System for providing interface and method for providing interface | |
EP2974745C0 (en) | Method for immune cell tracking | |
GB201415338D0 (en) | Cell processing method | |
SG11201508484QA (en) | Charging processing system | |
IL233451A0 (en) | Charging system and method | |
GB201416459D0 (en) | Detection method | |
PL2910913T3 (en) | Method and arrangement for providing weighing results | |
GB201414581D0 (en) | Fuel System and Method | |
GB201402174D0 (en) | Detection method | |
PL3134581T3 (en) | Method and soil-stabilizing means | |
GB201420712D0 (en) | Assessment method | |
GB201416715D0 (en) | Detection method | |
GB201412537D0 (en) | Testing smartcard |